1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Kinetik reported fourth-quarter 2025 total operating revenues of $430.4 million, up from $385.7 million a year earlier, and Adjusted EBITDA of $252.1 million, up from $237.5 million. Quarterly net income was driven by a $415.4 million gain on the sale of its EPIC Crude equity interest, and the company guided 2026 Adjusted EBITDA to $950 million to $1,050 million, which it said is a 7% increase at the midpoint.
Q4 2025 diluted EPS was $2.16 versus $0.01 in Q4 2024; Adjusted EBITDA was $252.1 million versus $237.5 million.
Net income including noncontrolling interest of $416.7 million includes a $415.4 million gain from the EPIC Crude divestiture completed October 31, 2025.
Full-year 2025 Adjusted EBITDA was $987.7 million; Q4 2025 Free Cash Flow was $(12.0) million versus $32.5 million a year earlier.
2026 guidance calls for Adjusted EBITDA of $950 million to $1,050 million and capital expenditures of $450 million to $510 million.
Ormat reported fourth-quarter 2025 revenue of $276.0 million, up 19.6%, led by Product and Energy Storage growth. Fourth-quarter GAAP diluted EPS fell to $0.50 from $0.67, and the company cited $12 million in impairment charges. The company also issued 2026 guidance calling for total revenues of $1,110 million to $1,160 million and Adjusted EBITDA of $615 million to $645 million.
Q4 2025 total revenues were $276.0 million, up 19.6% from $230.7 million; GAAP diluted EPS was $0.50 versus $0.67 a year earlier.
Full-year 2025 revenues were $989.6 million, up 12.5%; net income attributable to stockholders was $123.9 million, or $2.02 per diluted share, versus $2.04 in 2024.
2026 guidance: total revenues of $1,110 million to $1,160 million and Adjusted EBITDA of $615 million to $645 million.
Quarterly dividend of $0.12 per share, payable March 24, 2026, to holders of record as of March 10, 2026.
VSE Corporation reported fourth-quarter and full-year 2025 results on February 25, 2026, with revenue, GAAP net income and diluted EPS all higher than in 2024. The company also issued 2026 guidance that excludes the pending Precision Aviation Group acquisition, which is expected to close in the second quarter of 2026. For shareholders, the results show strong growth, though full-year free cash flow was only $6 million.
Q4 2025 revenue was $301.2 million, up 32%, and GAAP diluted EPS was $0.98 versus $0.51 a year earlier.
Full-year 2025 revenue was $1.1 billion, up 41%, with GAAP net income of $53.5 million and GAAP diluted EPS of $2.52.
2026 guidance excluding PAG calls for revenue growth of about 19% to 23% and Adjusted EBITDA margin of 16.8% to 17.3%.
Full-year 2025 operating cash flow was $27 million and free cash flow was $6 million; net debt was $223 million.
Donaldson reported second quarter fiscal 2026 results for the quarter ended January 31, 2026. Net sales rose 3.0% to $896.3 million, but GAAP net earnings fell 3.6% to $92.5 million and diluted EPS slipped to $0.78 from $0.79. The company lowered its adjusted fiscal 2026 EPS range and adjusted operating margin guidance, and agreed to acquire Facet for approximately $820 million in cash, expected to close in the second half of fiscal 2026.
Q2 net sales of $896.3 million, up 3.0%; GAAP net earnings of $92.5 million versus $95.9 million a year ago
Adjusted diluted EPS of $0.83, flat versus the prior year quarter
Adjusted fiscal 2026 EPS guidance narrowed to $3.93 to $4.01 from $3.95 to $4.11; adjusted operating margin guidance lowered to 16.0% to 16.4% from 16.2% to 16.8%
All-cash agreement to acquire Facet for approximately $820 million, expected to close in the second half of fiscal 2026
Sarepta Therapeutics said CEO Douglas Ingram has decided to retire as Chief Executive Officer by the end of 2026, or when a replacement is appointed, whichever comes first. The company has started a search of internal and external candidates for his successor. The filing does not name a successor or give a reason for the retirement.
Douglas Ingram notified the company of his retirement decision on February 25, 2026
Retirement is due by the end of 2026 or upon appointment of a replacement, whichever comes first
The company has commenced a search of internal and external candidates
LeMaitre Vascular reported preliminary fourth-quarter 2025 sales of $64.5 million, up 16%, with operating income of $18.8 million, up 47%. The company also guided to 2026 full-year sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01, and raised its quarterly dividend 25% and authorized a $100.0 million share repurchase program.
Q4 2025 diluted EPS was $0.68, up 39% from the prior-year quarter, and gross margin was 71.7%, up 240 basis points.
Full-year 2026 guidance calls for sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01.
On February 19, 2026, the board raised the quarterly dividend 25% to $0.25 per share, payable March 26, 2026, and authorized up to $100.0 million in buybacks through February 18, 2027.
Crescent Energy reported full-year 2025 net income attributable to the company of $132.9 million, compared with a $114.6 million loss in 2024, and a fourth-quarter net loss of $8.7 million, compared with a $118.0 million loss a year earlier. The company also issued 2026 guidance, including production of 320 to 335 MBoe/d, and raised its share repurchase authorization to $400 million, which gives it more room to buy back stock.
Full-year 2025 net income attributable to Crescent was $132.9 million, or $0.54 per diluted Class A share, versus a $114.6 million loss in 2024
Fourth-quarter 2025 net loss attributable to Crescent was $8.7 million, or $0.03 per share, versus a $118.0 million loss in the fourth quarter of 2024; fourth-quarter revenue was $865 million versus $875 million a year earlier
2026 guidance calls for total production of 320 to 335 MBoe/d and development capital of $1,325 million to $1,425 million
Board raised the share repurchase authorization to $400 million from $150 million and extended the program indefinitely; a $0.12 per share dividend is payable March 25, 2026
Ingevity reported a full-year 2025 net loss of $167.1 million, which the company attributed mainly to non-cash special charges tied to Advanced Polymer Technologies and Road Markings. Net sales from continuing operations fell 2.7% to $1.2 billion, while adjusted EPS from continuing operations rose 1.7% to $4.13. The company also gave 2026 guidance of adjusted EPS of $4.80 to $5.20 and said it has begun exploring strategic alternatives for those two businesses, which could change the company's portfolio.
Full-year 2025 net sales from continuing operations were $1.2 billion, down 2.7%; net loss from continuing operations was $150.3 million.
Fourth-quarter net loss of $84.6 million included $109.3 million in pre-tax non-cash special charges related to Road Markings.
2026 outlook: net sales of $1.1 billion to $1.2 billion, adjusted EBITDA of $380 million to $400 million, and adjusted EPS of $4.80 to $5.20.
Full-year 2025 free cash flow was $273.5 million; 2026 free cash flow is expected at $225 million to $250 million, excluding about $95 million in BASF litigation-related payments.
Chemed reported fourth-quarter 2025 revenue of $639.3 million, essentially flat year over year, while GAAP diluted EPS fell 9.0% to $5.48 and adjusted diluted EPS fell 6.0% to $6.42. The company guided to 2026 adjusted diluted EPS of $23.25 to $24.25, compared with 2025 adjusted EPS of $21.55, and said 55% of 2026 adjusted net income and adjusted EBITDA before Medicare Cap is expected in the second half.
Q4 2025 revenue was $639.3 million, essentially flat; GAAP diluted EPS was $5.48, down 9.0%, and adjusted diluted EPS was $6.42, down 6.0%.
VITAS net patient revenue rose 1.9% to $418.8 million, while Roto-Rooter revenue fell 3.7% to $220.6 million.
2026 guidance: adjusted diluted EPS of $23.25 to $24.25, versus $21.55 in 2025; Roto-Rooter adjusted EBITDA margin expected at 22.5% to 23.0%.
During the quarter the company repurchased 400,000 shares for $174.6 million; $127.3 million of repurchase authorization remained at December 31, 2025.
California Water Service Group reported fourth-quarter 2025 net income of $11.5 million, or $0.19 per diluted share, down 42% from $19.7 million, or $0.33, a year earlier, as revenue slipped to $220.0 million from $222.2 million. For the full year, net income fell to $128.2 million, or $2.15 per diluted share, from $190.8 million, or $3.25, and the company cited wet December weather and lower customer consumption. The company also agreed to buy Nexus Water Group's Nevada and Oregon subsidiaries for about $218 million, a deal expected to add about 36,000 connections and about $109 million to rate base, with closing targeted by the end of 2026 pending regulatory approvals.
Q4 2025 net income $11.5 million, or $0.19 per diluted share, versus $19.7 million, or $0.33, in Q4 2024
Full-year 2025 net income $128.2 million, or $2.15 per diluted share, versus $190.8 million, or $3.25, in 2024
Nexus acquisition price about $218 million, subject to closing adjustments; expected to close by end of 2026
Annual dividend raised to $1.24 per share, the 58th consecutive annual dividend, per the earnings release
Marriott Vacations Worldwide reported fourth quarter and full year 2025 results on February 25, 2026, including a fourth quarter net loss attributable to common stockholders of $431 million, compared with net income of $50 million a year earlier, driven by a $546 million non-cash impairment charge. Adjusted diluted earnings per share fell to $1.86 from $1.98, and the company issued full year 2026 guidance for adjusted EBITDA of $755 million to $780 million.
Q4 2025 net loss attributable to common stockholders was $431 million, or $12.43 per diluted share, versus net income of $50 million in Q4 2024.
Q4 2025 adjusted diluted EPS was $1.86, down from $1.98; consolidated contract sales were $458 million, down 4%.
Full year 2025 adjusted EBITDA was $751 million; 2026 guidance calls for adjusted EBITDA of $755 million to $780 million and adjusted diluted EPS of $7.05 to $7.80.
The company will hold a conference call on February 26, 2026 at 8:00 a.m. ET and plans to post a new investor presentation on its website that day.
Global Net Lease reported fourth-quarter 2025 revenue of $117.0 million, down from $137.8 million a year earlier, mainly due to asset dispositions. Q4 net income attributable to common stockholders was $37.2 million, compared with a net loss of $17.5 million, reflecting the gain on the McLaren Campus sale, while Q4 AFFO per share fell to $0.22 from $0.34. The company issued initial 2026 AFFO per share guidance of $0.80 to $0.84.
Q4 2025 revenue was $117.0 million versus $137.8 million in Q4 2024; full-year 2025 AFFO of $0.99 per share exceeded revised guidance of $0.95 to $0.97.
Full-year 2025 net loss attributable to common stockholders was $269.2 million, compared with $175.3 million in 2024.
Net debt fell by $2.2 billion in 2025; Net Debt to Adjusted EBITDA improved from 7.6x to 6.7x; Fitch upgraded the corporate credit rating to BBB-.
2026 guidance: AFFO per share of $0.80 to $0.84 and Net Debt to Adjusted EBITDA of 6.5x to 6.9x, assuming $250 million to $350 million of gross transaction volume.
H2O America reported full-year 2025 revenue of $800.6 million, up 7%, and adjusted diluted EPS of $2.99, up from $2.95 in 2024, near the top of its narrowed guidance range. It initiated 2026 standalone adjusted EPS guidance of $3.08-3.18, raised its long-term EPS growth target to 6-8%, and set a $2.7 billion 2026-30 capital spending plan, which matters to shareholders because it signals expected earnings growth alongside a larger investment program tied to pending Texas acquisitions.
2025 revenue was $800.6 million, up 7% from $748.4 million in 2024; GAAP net income was $102.6 million, up 9%.
2025 adjusted diluted EPS was $2.99 versus $2.95 in 2024; GAAP diluted EPS was $2.92 versus $2.87.
2026 standalone adjusted diluted EPS guidance is $3.08-3.18, excluding the pending Quadvest and Cibolo Valley acquisitions and their financing.
Fourth-quarter 2025 diluted EPS was $0.45 versus $0.68 a year earlier; the 2026-30 capital expenditures budget is $2.7 billion, a 31% increase over the prior five-year plan.
Northern Oil and Gas reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Fourth-quarter oil and gas sales fell to $447.7 million from $545.5 million a year earlier, and the company recorded a GAAP net loss of $70.7 million, which included a $268.5 million non-cash impairment, while production rose 6%. Full-year GAAP net income was $38.8 million, and the company closed its Joint Utica acquisition in February 2026 for a $464.6 million cash closing payment.
Q4 2025 oil and gas sales were $447.7 million, down from $545.5 million in Q4 2024, while production rose 6% to 140,064 Boe per day.
Q4 2025 GAAP net loss was $70.7 million, or $0.73 per diluted share, after a $268.5 million non-cash impairment charge.
Full-year 2025 GAAP net income was $38.8 million, or $0.39 per diluted share; full-year Adjusted EBITDA was $1.6 billion, up 1%.
2026 guidance: annual production of 139,000 to 143,000 Boe per day and capital expenditures of $850 million to $900 million in the low-activity scenario.
Synopsys reported first-quarter fiscal 2026 revenue of $2.409 billion, up from $1.455 billion a year earlier and at the high end of its prior guidance. GAAP net income fell to $65.0 million, or $0.34 per diluted share, from $295.7 million, while non-GAAP EPS rose to $3.77 from $3.03. The board also authorized up to $2.0 billion of stock repurchases, which the company may suspend or terminate at any time.
Revenue of $2.409 billion vs. $1.455 billion a year earlier, at the high end of prior guidance
GAAP net income of $65.0 million ($0.34 per diluted share) vs. $295.7 million ($1.89) a year earlier; restructuring charges were $118.3 million
Non-GAAP EPS of $3.77 vs. $3.03 a year earlier
Board replenished the stock repurchase program with up to $2.0 billion of authorization; full-year revenue target of $9.61 billion at the midpoint reiterated
Veeco reported fourth-quarter 2025 revenue of $165.0 million, down from $182.1 million a year earlier, and GAAP net income of $1.1 million, or $0.02 per diluted share, versus $15.0 million, or $0.26, in the prior-year quarter. For fiscal 2026 it guided to revenue of $740 million to $800 million and GAAP diluted EPS of $0.83 to $1.17, while the pending merger with Axcelis continues.
Q4 2025 non-GAAP EPS was $0.24, versus $0.41 in Q4 2024; Q4 2025 merger costs were $6.3 million
Full-year 2025 revenue was $664.3 million, versus $717.3 million in 2024; GAAP diluted EPS was $0.59, versus $1.23
Q1 2026 guidance: revenue of $150 million to $170 million and GAAP diluted EPS of ($0.03) to $0.07
The company cited a planned merger with Axcelis as part of its growth outlook
Nutanix reported second-quarter fiscal 2026 revenue of $722.8 million, up 10% from a year earlier, and GAAP net income of $103.0 million, up from $56.4 million. The same day, it agreed to sell 4,136,789 shares to AMD at $36.26 per share for $150 million, and the companies announced a multi-year partnership with AMD funding up to $100 million for Nutanix R&D and go-to-market work. The company guided third-quarter revenue to $680 million to $690 million and said supply chain constraints could affect the timing of near-term revenue and free cash flow.
Q2 GAAP net income was $103.0 million, or $0.36 per diluted share, versus $56.4 million, or $0.19 per diluted share, a year earlier.
Annual Recurring Revenue was $2.36 billion as of January 31, 2026, up 16% year over year; free cash flow was $191.4 million.
Q3 fiscal 2026 revenue outlook is $680 million to $690 million; fiscal 2026 revenue outlook is $2.80 billion to $2.84 billion.
AMD agreed to buy 4,136,789 Class A shares at $36.26 per share, or $150 million in cash, in a private placement; closing is subject to a Hart-Scott-Rodino waiting period.
Pursuit Attractions and Hospitality reported full-year 2025 revenue of $452.4 million, up 23.4% from 2024, and Adjusted EBITDA of $117.1 million, up $40.1 million. GAAP net income attributable to Pursuit fell to $22.7 million from $368.5 million, mainly because 2024 included the gain on the GES sale. The company guided to 2026 Adjusted EBITDA of $123 million to $133 million and set 2030 targets, and it expects to close the $78.4 million Flyover sale in spring 2026.
Full-year 2025 revenue was $452.4 million, up 23.4%; fourth-quarter revenue was $57.1 million, up 24.6%.
Full-year 2025 net income attributable to Pursuit was $22.7 million, or $0.80 per diluted share, versus $368.5 million in 2024; fourth-quarter net loss was $25.7 million.
2026 Adjusted EBITDA guidance is $123 million to $133 million, about 9% growth at the mid-point versus 2025.
Pursuit expects to sell Flyover Attractions to Brogent Technologies for about $78.4 million, with closing expected in spring 2026.
ADMA Biologics reported full-year 2025 total revenue of $510.2 million, up 20% from 2024, and reiterated its 2026-2029 financial guidance. GAAP net income fell to $146.9 million from $197.7 million, which included an $84.3 million one-time tax benefit in 2024. CFO Brad Tade is retiring and Terry Kohler becomes CFO on February 26, 2026.
Full-year 2025 revenue was $510.2 million, up from $426.5 million in 2024; ASCENIV revenue rose 51% to $363 million.
GAAP net income was $146.9 million in 2025 versus $197.7 million in 2024, which included an $84.3 million non-recurring tax benefit; Adjusted Net Income rose 35% to $160.8 million.
Terry Kohler, previously Executive Financial Advisor, was promoted to CFO and Treasurer effective February 26, 2026, succeeding Brad Tade.
Tade will serve as a consultant through July 31, 2026, at a monthly gross amount of $41,666.67; the company expects FY 2026 revenue to exceed $635 million.
Sarepta reported fourth-quarter 2025 total revenues of $442.9 million, down 33% from $658.4 million a year earlier, and a GAAP net loss of $412.2 million, compared with net income of $159.0 million in the prior-year quarter. For the full year, revenues rose 16% to $2,198.2 million, but the GAAP net loss was $713.4 million, compared with net income of $235.2 million in 2024.
Q4 2025 total revenues were $442.9 million versus $658.4 million in Q4 2024, mainly due to $273.8 million less ELEVIDYS net product revenue after the June 2025 suspension of shipments to non-ambulatory patients in the U.S.
Q4 2025 GAAP net loss was $412.2 million, or $3.93 per diluted share, including a $165.3 million increase in an inventory valuation reserve.
Full-year 2025 GAAP net loss was $713.4 million, or $7.13 per diluted share, versus net income of $235.2 million, or $2.34 per share, in 2024.
Cash, cash equivalents, restricted cash and investments were $953.8 million as of December 31, 2025, down from $1,503.5 million a year earlier.
TKO Group reported fourth quarter 2025 revenue of $1.038 billion, up 12%, and net income of $0.8 million, compared with a net loss of $60.9 million a year earlier. It also set 2026 targets of $5.675 billion to $5.775 billion in revenue and $2.240 billion to $2.290 billion in Adjusted EBITDA, and said it intends to launch up to $1 billion in share repurchases in March 2026.
Q4 2025 revenue $1.038 billion, up $110.2 million; Adjusted EBITDA $281.2 million, up 30%
Full year 2025 revenue $4.735 billion, down 3%; net income $546.2 million vs. net loss of $245.8 million in 2024
2026 targets: revenue $5.675 billion to $5.775 billion; Adjusted EBITDA $2.240 billion to $2.290 billion
Intends to repurchase up to $1.0 billion of Class A common stock, with launch expected in March 2026
Encore Capital Group reported fourth-quarter and full-year 2025 results, with full-year net income of $256.8 million, or $10.91 per diluted share, compared with a net loss of $139.2 million in 2024. The company projects 2026 earnings per share of $12.00, an increase of 10%, and global collections of $2.7 billion, up 5%.
Full-year 2025 revenues were $1.77 billion, up 34% from $1.32 billion in 2024.
Fourth-quarter 2025 net income was $76.7 million, or $3.37 per diluted share, versus a net loss of $225.3 million, or $9.42 per share, in the same quarter of 2024.
The company repurchased about 9% of its shares outstanding in 2025 for $89.5 million.
For 2026, the company expects global portfolio purchases of $1.4 billion to $1.5 billion.
Protagonist reported fourth-quarter 2025 license and collaboration revenue of $7.4 million, down from $170.6 million a year earlier, and a net loss of $44.4 million, or $0.69 per share, compared with net income of $131.7 million in the prior-year quarter. For the full year, revenue fell to $46.0 million and the net loss was $130.1 million, and the company said the decline reflects lower, highly variable milestone revenue.
Q4 2025 license and collaboration revenue was $7.4 million, versus $170.6 million in Q4 2024, a decrease of $163.2 million.
Q4 2025 net loss was $44.4 million, or $0.69 per share, versus net income of $131.7 million, or $2.11 per basic share, a year earlier.
Full-year 2025 net loss was $130.1 million, or $2.05 per share, compared with net income of $275.2 million in 2024.
Cash, cash equivalents and marketable securities were $646.0 million at December 31, 2025, which the company expects to fund operations through at least the end of 2028.
Arcus Biosciences reported fourth-quarter and full-year 2025 results on February 25, 2026. Revenue declined and the net loss widened for both periods, and the company gave 2026 GAAP revenue guidance of $45 million to $55 million. Arcus and Gilead are winding down the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies, and the company expects R&D expenses to decrease meaningfully in 2026.
Full-year 2025 revenue was $247 million, down from $258 million in 2024; net loss was $353 million, or $3.29 per share, versus $283 million, or $3.14 per share in 2024
Fourth-quarter 2025 revenue was $33 million, down from $36 million; net loss was $106 million, compared with $94 million a year earlier
Company expects GAAP revenue of $45 million to $55 million for full-year 2026
Cash, cash equivalents and marketable securities were $1.0 billion at December 31, 2025, versus $992 million a year earlier, with funding expected until at least the second half of 2028
Southwest Gas Holdings said CEO and President Karen S. Haller will resign effective May 8, 2026, and will stay on as an employee and advisor through December 31, 2026. The board appointed Justin Lee Brown as President and CEO effective the same date, and he is nominated for the board at the 2026 annual meeting. The filing states Ms. Haller's resignation was not the result of any disagreement with the companies on operations, policies or practices.
Karen S. Haller resigns as President, CEO and director of Southwest Gas Holdings, effective May 8, 2026; director role ends at the 2026 annual meeting on May 7, 2026
Justin Lee Brown appointed President and CEO of Southwest Gas Holdings and CEO of Southwest Gas Corporation, effective May 8, 2026
Brown's compensation: $900,000 base salary, 110% target cash incentive, $3.1 million one-time PSU award, and 330% target long-term incentive beginning in 2027
Haller will receive a monthly salary of $95,000 while serving as an advisor through December 31, 2026
Agilent reported first-quarter fiscal 2026 revenue of $1.80 billion, up 7.0% reported and 4.4% on a core basis, and GAAP EPS of $1.07, down 4% from a year earlier. The company raised its fiscal 2026 reported revenue outlook to $7.3 billion to $7.5 billion and increased its non-GAAP EPS range to $5.90 to $6.04, which matters to shareholders because the headline revenue and non-GAAP earnings measures moved up while GAAP profit declined.
Q1 revenue $1.80 billion, up 7.0% reported and 4.4% core; non-GAAP EPS $1.36, up 4% from $1.31
GAAP net income $305 million, or $1.07 per share, versus $318 million, or $1.11, in Q1 2025
FY2026 revenue outlook $7.3 billion to $7.5 billion; non-GAAP EPS $5.90 to $6.04
Q2 2026 revenue guidance $1.79 billion to $1.82 billion; non-GAAP EPS $1.39 to $1.42
Sterling Infrastructure reported fourth quarter and full year 2025 results and issued full year 2026 guidance in a press release furnished with the 8-K. Fourth quarter revenue rose 51% on a GAAP basis to $755.6 million, with the CEC acquisition contributing $129.1 million, while GAAP diluted EPS fell to $2.81 from $3.64 because the prior-year quarter included a one-time $91 million pre-tax gain from deconsolidating the RHB joint venture. The company expects 2026 revenue of $3.05 billion to $3.20 billion and adjusted diluted EPS of $13.45 to $14.05.
Fourth quarter 2025 revenue was $755.6 million, up 51% on a GAAP basis; CEC acquisition contributed $129.1 million.
Fourth quarter GAAP diluted EPS was $2.81 versus $3.64 a year earlier, which included a one-time RHB gain; adjusted diluted EPS was $3.08, up 78%.
Full year 2025 revenue was $2.49 billion, up 18% on a GAAP basis; adjusted diluted EPS was $10.88 versus $7.09.
2026 guidance: revenue of $3.05 billion to $3.20 billion and adjusted diluted EPS of $13.45 to $14.05.
Dorman Products reported fourth quarter and full year 2025 results on February 25, 2026. Full-year net sales rose 6.0% to $2.13 billion and adjusted diluted EPS rose 24% to $8.87, but fourth-quarter diluted EPS fell 79% to $0.38 after a $51.1 million non-cash goodwill impairment tied to the Heavy Duty segment. For 2026, the company guided to adjusted diluted EPS of $8.10 to $8.50, a decline of 9% to 4% from 2025, while GAAP diluted EPS is guided to rise 14% to 20%.
Q4 2025 net sales were $537.9 million, up 0.8%; adjusted diluted EPS was $2.17, down 1%.
Full-year 2025 net sales were $2.13 billion, up 6.0%; diluted EPS was $6.64, up 8%.
2026 guidance: net sales up 7% to 9%; diluted EPS $7.57 to $7.97; adjusted diluted EPS $8.10 to $8.50.
Conference call and webcast scheduled for February 26, 2026, at 8:00 a.m. Eastern time.
Sezzle reported fourth-quarter and full-year 2025 results with revenue and net income up sharply from 2024 and raised its FY2026 Adjusted Net Income per Diluted Share guidance to $4.70 from $4.35. The company also said its 2024 Consolidated Statements of Cash Flows should no longer be relied upon because it misclassified notes receivable purchases and repayments as investing activities; the restatement changes cash flow classification only, with no effect on the balance sheet or income statement.
Q4 2025 Total Revenue rose 32.2% year over year to $129.9 million; Net Income was $42.7 million, or $1.21 per diluted share.
FY2025 Net Income rose 69.5% to $133.1 million, or $3.72 per diluted share; Adjusted Net Income was $128.4 million.
FY2026 guidance: Adjusted Net Income per Diluted Share raised to $4.70 from $4.35; Total Revenue growth of 25% to 30%; Adjusted Net Income of $170.0 million.
2024 operating cash flow restated to $130.6 million from $40.9 million; $89.7 million reclassified from investing activities. Determined February 19, 2026; no amended 10-K or 10-Q filings planned.
Salesforce reported fourth-quarter fiscal 2026 revenue of $11.2 billion, up 12% year-over-year, and GAAP diluted net income per share of $2.07 versus $1.75 a year earlier. The company initiated full-year fiscal 2027 revenue guidance of $45.8 billion to $46.2 billion, up 10% to 11%, and announced a $50 billion share repurchase authorization and a higher quarterly dividend of $0.44 per share.
Q4 FY26 revenue $11.2 billion, up 12% Y/Y; GAAP diluted EPS $2.07 vs. $1.75 in Q4 FY25
FY27 revenue guidance $45.8 billion to $46.2 billion; GAAP diluted EPS guidance $7.85 to $7.93
MYR Group reported fourth-quarter and full-year 2025 results in a press release furnished with this 8-K. Full-year revenue rose to $3.66 billion from $3.36 billion, and net income rose to $118.4 million, or $7.53 per diluted share, from $30.3 million, or $1.83, a year earlier. Backlog reached $2.82 billion at year end, and the release contains no financial guidance for 2026.
Q4 2025 revenue was $973.5 million, up 17.3% from Q4 2024; diluted EPS was $2.33 versus $0.99
Full-year 2025 revenue was $3.66 billion versus $3.36 billion in 2024; net income was $118.4 million versus $30.3 million
Backlog was $2.82 billion at December 31, 2025, up 9.6% from $2.58 billion at December 31, 2024
Cash and cash equivalents were $150.2 million; $408.3 million was available under the $490 million revolving credit facility
Penumbra reported fourth quarter 2025 revenue of $385.4 million, up 22.1%, and net income of $47.3 million, compared with $33.7 million a year earlier. Full-year 2025 revenue rose 17.5% to $1,403.7 million and net income reached $177.7 million, versus $14.0 million in 2024. The company will not provide 2026 financial guidance or hold a conference call because of its proposed acquisition by Boston Scientific.
Q4 2025 diluted EPS was $1.20, compared with $0.86 in Q4 2024.
Full-year 2025 income from operations was $189.2 million, compared with $9.3 million in 2024.
No financial guidance for full-year 2026 because of the proposed acquisition by Boston Scientific Corporation (NYSE: BSX).
Range Resources reported fourth quarter 2025 revenues and other income of $820 million, up 31% from a year earlier, with net income of $179 million, or $0.75 per diluted share, compared with $94.8 million, or $0.39, in the prior-year quarter. The company also raised its stock repurchase authorization to $1.5 billion and provided 2026 guidance, including all-in capital spending of $650 million to $700 million and production of 2.35 to 2.40 billion cubic feet equivalent per day.
Q4 2025 net income was $179 million ($0.75 per diluted share), up from $94.8 million ($0.39) in Q4 2024; full-year 2025 net income was $658 million ($2.74 per diluted share).
Q4 2025 included a $33 million mark-to-market derivative gain; adjusted diluted EPS, comparable to analysts' estimates, was $0.82.
The board increased the repurchase program to $1.5 billion of current availability as of February 24, 2026.
2026 guidance calls for all-in capital spending of $650 million to $700 million and production of 2.35 to 2.40 Bcfe per day.
Alkermes said CEO Richard Pops will retire effective July 31, 2026, and the board appointed COO Blair Jackson as CEO effective August 1, 2026. Pops will remain non-executive Chairman and serve as Senior Advisor through December 31, 2026, so the filing describes a planned succession rather than a change in financial results.
Richard Pops retires as CEO effective July 31, 2026; Blair Jackson becomes CEO effective August 1, 2026
Pops to serve as non-executive Chairman and Senior Advisor through December 31, 2026
Pops' letter agreement includes a $75,000 monthly cash retainer while a Senior Advisor and a 2026 RSU award with a grant value of $2,687,500
Jackson has been Executive Vice President and Chief Operating Officer since January 2021 and was interim principal financial officer from February 2024 to September 2025
Alabama Power and Georgia Power, subsidiaries of Southern Company, entered into loan guarantee agreements and credit facilities with the U.S. Department of Energy and the Federal Financing Bank on February 20, 2026. Southern Company itself is not a party to the loan documents, but the borrowings will be full recourse, senior unsecured obligations of the two utilities, which matters to shareholders because it adds debt at the subsidiary level.
Alabama Power's facility may not exceed approximately $4.1 billion; Georgia Power's may not exceed approximately $22.4 billion
Georgia Power requested initial advances of approximately $1.0 billion on February 20, 2026, and expects to receive them in March 2026
Advances bear interest at the U.S. Treasury rate plus 0.375%, with a final scheduled maturity of December 10, 2055
Advances are available until the earliest of September 15, 2033, full use of the facility amount, or termination after an event of default
TJX reported fourth-quarter fiscal 2026 net sales of $17.7 billion, up 9%, and diluted earnings per share of $1.58, up 28%, including a litigation settlement benefit; adjusted EPS was $1.43, up 16%. The company guided fiscal 2027 diluted EPS to $4.93 to $5.02 and said it intends to raise its quarterly dividend 13% to $.48 per share and repurchase $2.50 to $2.75 billion of stock.
Q4 net sales $17.7 billion, up 9%; consolidated comparable sales up 5%
Q4 diluted EPS $1.58 including a $.15 net benefit from a litigation settlement; adjusted EPS $1.43, up 16%
FY27 guidance: full-year diluted EPS $4.93 to $5.02 and first-quarter diluted EPS $.97 to $.99
Plans to buy back $2.50 to $2.75 billion of stock in FY27 and a new $3.0 billion authorization; dividend increase expected to be declared in March 2026
Southwest Gas Holdings reported fourth-quarter 2025 diluted EPS of $1.43, up from $1.28 a year earlier, while consolidated operating revenues fell to $480.7 million from $553.1 million. The company also raised its quarterly dividend 4% to $0.645 per share starting in the second quarter of 2026 and initiated 2026 EPS guidance of $4.17 to $4.32 per share.
Q4 2025 diluted EPS $1.43 vs. $1.28 a year earlier; adjusted EPS from continuing operations $1.36 vs. $1.20
Q4 2025 consolidated operating revenues $480.7 million vs. $553.1 million; full year $1.94 billion vs. $2.48 billion
2026 EPS from continuing operations guidance of $4.17 to $4.32; 2026 capital expenditures of about $1.25 billion
Quarterly common dividend raised 4% to $0.645 per share, beginning with the second quarter of 2026
Acadia Healthcare reported fourth-quarter 2025 revenue of $821.5 million, up 6.1% year over year, but posted a net loss of $(13.02) per diluted share compared with net income of $0.35 a year earlier, driven by a $996.2 million non-cash goodwill impairment charge. Adjusted earnings per diluted share fell to $0.07 from $0.64, and the company also gave 2026 guidance calling for revenue of $3.37 to $3.45 billion and adjusted EBITDA of $575 to $610 million, with Debbie Osteen announced as chief executive officer.
Q4 2025 adjusted EBITDA was $99.8 million, compared with $153.1 million a year earlier, including a $52.7 million adjustment to professional and general liability reserves.
Full-year 2025 revenue was $3,312.8 million, up 5.0%, while the full-year net loss was $(12.16) per diluted share.
2026 guidance: revenue of $3.37 to $3.45 billion, adjusted EBITDA of $575 to $610 million, and adjusted earnings per diluted share of $1.30 to $1.55.
Debbie Osteen is identified as Chief Executive Officer; the conference call is scheduled for February 25, 2026 at 9:00 a.m. Eastern Time.
Alkermes reported that 2025 total revenues fell to $1.48 billion from $1.56 billion in 2024, and GAAP net income dropped to $242 million from $367 million. The company projected a 2026 GAAP net loss of $115 million to $135 million, with total revenues of $1.73 billion to $1.84 billion, after completing its Avadel acquisition on February 12, 2026. For shareholders, the results show lower 2025 revenue and profit, and the company expects a loss in 2026.
FY2025 total revenues were $1.48 billion versus $1.56 billion in FY2024; diluted GAAP EPS was $1.43 versus $2.17.
Q4 2025 GAAP net income was $49.3 million versus $146.5 million in Q4 2024.
2026 expectations: total revenues of $1.73 billion to $1.84 billion and GAAP net loss of $115 million to $135 million.
Avadel acquisition closed February 12, 2026, funded with about $775 million of balance sheet cash and term loans totaling $1.525 billion due in 2031.
Steven Madden reported fourth quarter 2025 revenue up 29.4% to $753.7 million, with GAAP diluted EPS falling to $0.32 from $0.49 a year earlier. For full year 2025, revenue rose 11.0% to $2,534.1 million while GAAP diluted EPS fell to $0.63 from $2.35, and the company expects 2026 revenue to grow 9% to 11% but is not providing earnings guidance due to tariff uncertainty.
Q4 2025 revenue rose 29.4% to $753.7 million; GAAP diluted EPS was $0.32 versus $0.49, and adjusted diluted EPS was $0.48 versus $0.55.
Full-year 2025 revenue rose 11.0% to $2,534.1 million; GAAP diluted EPS was $0.63 versus $2.35, and adjusted diluted EPS was $1.70 versus $2.67.
2026 outlook calls for revenue growth of 9% to 11%; no earnings guidance is provided because of tariff uncertainty.
Board declared a quarterly cash dividend of $0.21 per share, payable March 20, 2026 to holders of record as of March 11, 2026.
Owens Corning reported a fourth-quarter 2025 net loss from continuing operations of $282 million, compared with earnings of $126 million a year earlier, and a full-year net loss of $188 million, compared with earnings of $947 million in 2024. The results include non-cash, pre-tax impairment charges of $1.2 billion for the Doors business, while full-year net sales rose 3% to $10.1 billion. For shareholders, the charges sharply reduced reported profit, and the company guided to first-quarter 2026 revenue of $2.1 billion to $2.2 billion.
Fourth-quarter net sales were $2.14 billion, down 17% from $2.57 billion a year earlier; full-year net sales were $10.1 billion, up 3%.
Full-year diluted EPS from continuing operations was $(2.24), versus $10.79 in 2024; adjusted diluted EPS was $12.05, versus $14.85.
The company returned $1.0 billion to shareholders in 2025 through dividends and share repurchases and reported operating cash flow of $1.8 billion.
For first-quarter 2026, Owens Corning expects revenue from continuing operations of $2.1 billion to $2.2 billion and adjusted EBITDA margin in the mid-teens.
LivaNova reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year revenue rose 10.7% to $1.39 billion and adjusted diluted EPS reached $3.90, but a $365.6 million SNIA environmental liability expense produced a GAAP diluted loss of $4.45 per share. The company expects 2026 adjusted diluted EPS of $4.15 to $4.25, which sets the earnings outlook shareholders will track in the coming year.
Fourth-quarter 2025 revenue was $360.9 million, up 12.1% on a reported basis; GAAP diluted EPS was $0.56 versus $1.02, and adjusted diluted EPS was $0.86 versus $0.81.
Full-year 2025 revenue was $1.39 billion, up 10.7%; GAAP diluted loss was $4.45 per share, including the $365.6 million SNIA charge, and adjusted diluted EPS was $3.90 versus $3.38.
2026 guidance calls for constant-currency revenue growth of 6.0% to 7.0%, adjusted diluted EPS of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million.
Increased CMS reimbursement for VNS Therapy for drug-resistant epilepsy takes effect January 1, 2026, with hospital outpatient payments rising about 48% for new patient implants.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.